U.S. Food & Drug Administration Approves Roche's Tecentriq in Combination With a Fluoropyrimidine, Oxaliplatin for Adjuvant Treatment of a Certain Type of Stage III Colon Cancer
October 10, 2026
October 10, 2026
BASEL, Switzerland, Oct. 10 (TNSrep) -- Roche, a biotech company, issued the following news release:
* * *
FDA approves Roche's Tecentriq in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of a certain type of stage III colon cancer
* FDA approval is based on results from the landmark phase III ATOMIC study, published in The New England Journal of Medicine, which showed Tecentriq plus chemotherapy reduced the risk of dise . . .
* * *
FDA approves Roche's Tecentriq in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of a certain type of stage III colon cancer
* FDA approval is based on results from the landmark phase III ATOMIC study, published in The New England Journal of Medicine, which showed Tecentriq plus chemotherapy reduced the risk of dise . . .
